ES2545152T3 - Procedimiento para la preparación de extractos secos - Google Patents
Procedimiento para la preparación de extractos secos Download PDFInfo
- Publication number
- ES2545152T3 ES2545152T3 ES12762228.0T ES12762228T ES2545152T3 ES 2545152 T3 ES2545152 T3 ES 2545152T3 ES 12762228 T ES12762228 T ES 12762228T ES 2545152 T3 ES2545152 T3 ES 2545152T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- procedure
- preparation
- infection
- supernatant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000000284 extract Substances 0.000 title description 4
- 239000000419 plant extract Substances 0.000 abstract description 3
- 230000001476 alcoholic effect Effects 0.000 abstract description 2
- 239000006228 supernatant Substances 0.000 abstract 4
- 238000000605 extraction Methods 0.000 abstract 2
- 238000000926 separation method Methods 0.000 abstract 2
- 240000003409 Gentiana lutea Species 0.000 abstract 1
- 235000002873 Gentiana lutea Nutrition 0.000 abstract 1
- 235000002343 Primula veris Nutrition 0.000 abstract 1
- 244000072254 Primula veris Species 0.000 abstract 1
- 240000006028 Sambucus nigra Species 0.000 abstract 1
- 235000003142 Sambucus nigra Nutrition 0.000 abstract 1
- 240000001519 Verbena officinalis Species 0.000 abstract 1
- 235000018718 Verbena officinalis Nutrition 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 235000008995 european elder Nutrition 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 239000000126 substance Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002962 plaque-reduction assay Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000009583 Sinupret Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Abstract
Procedimiento para la preparación de extractos secos de plantas, con las etapas: a.) extracción alcohólica/acuosa de Rumicis herba 5 , Verbena officinalis, Sambucus nigra, Primula veris y Gentiana lutea, b.) separación del sobrenadante, c.) extracción acuosa del residuo, d.) separación del sobrenadante, e.) combinación de los sobrenadantes obtenidos de b.) y d.), f.) secado de los sobrenadantes y obtención del extracto seco de planta.
Description
5
15
25
35
45
55
65
E12762228
11-08-2015
caolín y bentonita y i) lubricantes, por ejemplo talco, estearato de calcio y estearato de magnesio y polietilglicoles sólidos o mezclas de sustancias enumeradas desde a) hasta i). Los comprimidos, grageas, cápsulas, pastillas y granulados pueden estar provistos de los revestimientos y cubiertas habituales, opcionalmente opacificantes, por ejemplo tales como hipromelosa no concluyente, celulosa microcristalina, ácido esteárico, dióxido de titanio, y también estar formulados de manera que estos o los principios activos den retraso opcionalmente a solo o preferentemente a una parte determinada del tracto intestinal, en el que pueden utilizarse como masas de integración, por ejemplo, sustancias poliméricas y ceras.
EJEMPLOS
Estos ejemplos sirven exclusivamente para explicar la invención, sin limitar la invención a estos ejemplos.
En lo sucesivo, "extracto seco" (ES)" quiere decir el extracto seco de plantas preparado según la invención.
Ejemplo 1:
La actividad antiviral del extracto seco según la invención se probó en una multitud de ensayos in vitro.
En estos ensayos, se analizó en primer lugar el efecto general que daña la célula (citotóxico) del extracto seco según la invención en el Sinupret® conocido (alcohólico/acuoso). Tras la incubación de las líneas celulares adecuadas (por ejemplo, HeLa, HEp-2) con los distintos virus durante un período de una hora, las líneas celulares infectadas se trataron con diferentes concentraciones, y a continuación se midió el efecto sobre la multiplicación vírica.
La determinación cuantitativa de la actividad antiviral in vitro se llevó a cabo sobre la detección de un efecto citopatógeno (adenovirus 5), en ensayo de reducción de placas (FluA, HRV14, VSR) y en ensayos de inmunoabsorción enzimática específicos de virus (ELISA; Adeno5, VSR).
En la detección de un efecto citopatógeno, las células de crecimiento confluente sensibles a los virus se infectan con una solución de virus definida (MDI, multiplicidad de infección). Después de una hora de incubación, se extrae el inóculo de virus y se lava la capa celular. A continuación se realiza la adición de las concentraciones de sustancias fisiológicas. Los respectivos lotes de pruebas se cultivan hasta que se observa en los controles de virus no tratados microscópicamente un efecto citopatógeno (ECP) al 70-90 %, que se muestra como áreas celulares destruidas. La superficie de las áreas celulares destruidas se define como infección al 100 %. En comparación, se evaluaron las superficies celulares de los respectivos lotes de pruebas, de manera que los efectos inhibidores de las sustancias que van a analizarse pueden mostrarse como inhibición porcentual ( % de inhibición).
En los ensayos de reducción de placas, las células de crecimiento confluente sensibles a los virus se infectan con una solución de virus definida (MDI, multiplicidad de infección). Después de una hora de incubación, se extrae el inóculo de virus y se lava la capa celular infectada. A continuación se realiza la adición de las concentraciones de sustancias fisiológicas así como de un componente del medio sólido (agarosa o metilcelulosa) y se volvió a incubar. Mediante los componentes sólidos en el medio superpuesto se delimita la superficie de infección, de modo que se forma un foco de células infectadas (“placa”). Los respectivos lotes de pruebas se cultivan hasta que se observa en los controles de virus no tratados microscópicamente el número de placas ajustado (MDI). Mediante la fijación y la tintura de las áreas celulares las placas de virus pueden visualizarse como granjas de color claro en áreas celulares de color oscuro. La determinación del número de placas se realiza con ayuda de los sistemas de procesamiento de imágenes. El número de placas del control no tratado se define como infección al 100 %. Por el contrario, el número de placas de los respectivos lotes de pruebas se evalúa de manera que los efectos inhibidores de las sustancias de ensayo pueden mostrarse como inhibición porcentual ( % de inhibición).
En ELISA se analiza la producción de virus. Las tiras de prueba con anticuerpos contra los virus específicos unen virus existentes en el sobrenadante del cultivo celular de las líneas celulares infectadas. Para hacer visible la reacción, se utiliza un anticuerpo de detección específico de patógenos marcado con peroxidasa. Tras la adición de una sustancia/cromógeno así como de peróxido de hidrógeno y tetrametilbencidina se realza una reacción de color. La intensidad de la coloración se determina fotométricamente y es proporcional al contenido de antígenos de virus. El análisis de la producción de virus en células infectadas y tratadas se realiza tras la infección de células de crecimiento confluente sensibles a los virus con una solución de virus definida (MDI, multiplicidad de infección). Después de una hora de incubación, se extrae el inóculo de virus y se lava la capa celular infectada. A continuación se realiza la adición de las concentraciones de sustancias fisiológicas. Los respectivos lotes de pruebas se cultivan hasta que se observa en los controles de virus no tratados microscópicamente un efecto citopatógeno (ECP) al 7090 %. Los virus recién sintetizados se encuentran en este estado en el sobrenadante del cultivo celular. El valor de absorbancia fotométrico determinado de los controles no tratados se definen como infección al 100 %. En comparación, los valores extinción de los respectivos lotes de pruebas se evalúan de manera que los efectos inhibidores de las sustancias de ensayo pueden representarse como inhibición porcentual ( % de inhibición).
En todos los ensayos se muestra una clara inhibición de la multiplicación vírica, es decir, una reducción de la carga viral, véase la Figura 1.
7
Claims (1)
-
imagen1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11178206A EP2559438A1 (de) | 2011-08-19 | 2011-08-19 | Verfahren zur Herstellung von Trockenextrakten |
EP11178206 | 2011-08-19 | ||
EP11193734 | 2011-12-15 | ||
EP11193734 | 2011-12-15 | ||
EP12170125 | 2012-05-30 | ||
EP12170125 | 2012-05-30 | ||
PCT/EP2012/066212 WO2013026830A1 (de) | 2011-08-19 | 2012-08-20 | Verfahren zur herstellung von trockenextrakten |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2545152T3 true ES2545152T3 (es) | 2015-09-08 |
Family
ID=46889004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12762228.0T Active ES2545152T3 (es) | 2011-08-19 | 2012-08-20 | Procedimiento para la preparación de extractos secos |
Country Status (25)
Country | Link |
---|---|
US (3) | US9486489B2 (es) |
EP (2) | EP2744504B1 (es) |
JP (1) | JP6039670B2 (es) |
KR (1) | KR101976560B1 (es) |
CN (2) | CN106421162B (es) |
AU (1) | AU2012298534B2 (es) |
BR (1) | BR112014003779B1 (es) |
CA (1) | CA2845055C (es) |
CL (1) | CL2014000406A1 (es) |
CO (1) | CO6970591A2 (es) |
DK (1) | DK2744504T3 (es) |
EA (1) | EA025133B1 (es) |
ES (1) | ES2545152T3 (es) |
HR (1) | HRP20150883T1 (es) |
HU (1) | HUE025364T2 (es) |
IL (1) | IL231046A (es) |
MX (1) | MX348056B (es) |
PL (1) | PL2744504T3 (es) |
PT (1) | PT2744504E (es) |
RS (1) | RS54177B1 (es) |
SG (1) | SG2014014583A (es) |
SI (1) | SI2744504T1 (es) |
UA (1) | UA114893C2 (es) |
WO (1) | WO2013026830A1 (es) |
ZA (1) | ZA201401078B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8805838B1 (en) * | 2009-12-22 | 2014-08-12 | Amazon Technologies, Inc. | Systems and methods for automatic item classification |
CN108463232A (zh) * | 2015-08-31 | 2018-08-28 | Hsrx集团有限公司 | 用于治疗和预防病毒感染的组合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19525026A1 (de) | 1995-07-10 | 1997-01-16 | Plantamed Arzneimittel Gmbh | Verfahren zur Herstellung von pharmazeutischen Zubereitungen mit höherem Gehalt an etherischen Ölen und Phenolen |
DE10112167C2 (de) | 2001-03-12 | 2003-02-13 | Bionorica Ag | Verfahren zur schonenden Gewinnung von Trockenextrakten |
DE10112168A1 (de) | 2001-03-12 | 2002-10-02 | Bionorica Arzneimittel Ag | Trockenextrakt mit einstellbarem Gehalt an lipophilen und hydrophilen Substanzen und Verfahren zur Herstellung desselben |
DE10127897B4 (de) | 2001-06-08 | 2006-04-20 | Bionorica Ag | Manteltablette mit Pflanzentrockenextrakten |
US20030003212A1 (en) | 2001-06-13 | 2003-01-02 | Givaudan Sa | Taste modifiers |
DE10341579A1 (de) * | 2003-09-09 | 2005-04-07 | Bionorica Ag | Verwendung von Extrakten aus Gentiana lutea als antimikrobiell wirkendes Mittel |
EP1858500A4 (en) | 2005-03-16 | 2013-01-16 | Genetic Health Entpr Pty Ltd | MEDICAL COMPOSITIONS OF SALTS, CHELATES AND / OR FREE ACIDS OF ORGANIC ALPHA HYDROXYLIC ACIDS AND ASSOCIATED PROCEDURES AND METHODS |
US20070196298A1 (en) | 2005-05-31 | 2007-08-23 | Kostick Richard H | Cosmetic and dermatological formulations with natural pigments and methods of use |
DE202005017669U1 (de) * | 2005-11-11 | 2006-01-12 | Bionorica Ag | Antimikrobielles Mittel aus Pflanzenextrakten |
DE102005053926B3 (de) | 2005-11-11 | 2007-06-28 | Bionorica Ag | Verwendung eines antibakteriellen Mittels aus einer Mischung aus Pflanzendrogen oder Extrakten daraus |
CN100475802C (zh) | 2005-12-20 | 2009-04-08 | 苏州市思源医药科技有限公司 | 制备杨梅花青素提取物的方法,杨梅花青素提取物及其用途 |
DE102007052223A1 (de) * | 2007-10-31 | 2009-05-14 | Bionorica Ag | Hydrolysate aus Pflanzenextrakten sowie diese enthaltendes antibakterielles Mittel |
-
2012
- 2012-08-20 SI SI201230280T patent/SI2744504T1/sl unknown
- 2012-08-20 BR BR112014003779-5A patent/BR112014003779B1/pt active IP Right Grant
- 2012-08-20 RS RS20150551A patent/RS54177B1/en unknown
- 2012-08-20 CA CA2845055A patent/CA2845055C/en active Active
- 2012-08-20 WO PCT/EP2012/066212 patent/WO2013026830A1/de active Application Filing
- 2012-08-20 EP EP12762228.0A patent/EP2744504B1/de active Active
- 2012-08-20 CN CN201610854819.3A patent/CN106421162B/zh active Active
- 2012-08-20 MX MX2014001994A patent/MX348056B/es active IP Right Grant
- 2012-08-20 PL PL12762228T patent/PL2744504T3/pl unknown
- 2012-08-20 PT PT127622280T patent/PT2744504E/pt unknown
- 2012-08-20 DK DK12762228.0T patent/DK2744504T3/en active
- 2012-08-20 ES ES12762228.0T patent/ES2545152T3/es active Active
- 2012-08-20 KR KR1020147007049A patent/KR101976560B1/ko active IP Right Grant
- 2012-08-20 HU HUE12762228A patent/HUE025364T2/en unknown
- 2012-08-20 SG SG2014014583A patent/SG2014014583A/en unknown
- 2012-08-20 JP JP2014526466A patent/JP6039670B2/ja active Active
- 2012-08-20 EP EP15171289.0A patent/EP2946783A1/de not_active Withdrawn
- 2012-08-20 US US14/239,226 patent/US9486489B2/en active Active
- 2012-08-20 UA UAA201402741A patent/UA114893C2/uk unknown
- 2012-08-20 EA EA201490478A patent/EA025133B1/ru unknown
- 2012-08-20 AU AU2012298534A patent/AU2012298534B2/en active Active
- 2012-08-20 CN CN201280045205.0A patent/CN103826649B/zh active Active
-
2014
- 2014-02-12 ZA ZA2014/01078A patent/ZA201401078B/en unknown
- 2014-02-19 IL IL231046A patent/IL231046A/en active IP Right Grant
- 2014-02-19 CL CL2014000406A patent/CL2014000406A1/es unknown
- 2014-03-19 CO CO14058565A patent/CO6970591A2/es unknown
-
2015
- 2015-08-19 HR HRP20150883TT patent/HRP20150883T1/hr unknown
-
2016
- 2016-09-16 US US15/267,448 patent/US9980999B2/en active Active
-
2018
- 2018-04-30 US US15/966,198 patent/US10485841B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yeganeh et al. | Autophagy activation is required for influenza A virus-induced apoptosis and replication | |
Gabryel et al. | Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation | |
Hudson et al. | Antiviral activities of hypericin | |
Rohrlack et al. | Isolation, characterization, and quantitative analysis of microviridin J, a new Microcystis metabolite toxic to Daphnia | |
Arai et al. | Epigenetic assessment of environmental chemicals detected in maternal peripheral and cord blood samples | |
Li et al. | Optimization of on-chip bacterial culture conditions using the Box-Behnken design response surface methodology for faster drug susceptibility screening | |
Donalisio et al. | In vitro anti-Herpes simplex virus activity of crude extract of the roots of Nauclea latifolia Smith (Rubiaceae) | |
Müller et al. | Development of a high-throughput colorimetric Zika virus infection assay | |
Ramalingam et al. | Anti-dengue activity of Andrographis paniculata extracts and quantification of dengue viral inhibition by SYBR green reverse transcription polymerase chain reaction | |
ES2545152T3 (es) | Procedimiento para la preparación de extractos secos | |
Gavanji et al. | Cytotoxic activity of herbal medicines as assessed in vitro: a review | |
Heiser et al. | Activation of DNA damage repair pathways by murine polyomavirus | |
Denesvre et al. | Chicken skin virome analyzed by high-throughput sequencing shows a composition highly different from human skin | |
Uma et al. | Neuroprotective effects of polyherbal formulation (Indian) on noni scopolamineinduced memory impairment in mice | |
Huang et al. | Aquatic birnavirus-induced ER stress-mediated death signaling contribute to downregulation of Bcl-2 family proteins in salmon embryo cells | |
CN102023207B (zh) | 在整体斑马鱼上进行酶联免疫吸附检测的方法及其应用 | |
Yamada et al. | Laboratory diagnosis of dengue virus infection by reverse transcriptase polymerase chain reaction (RT-PCR) and IgM-capture enzyme-linked immunosorbent assay (ELISA) | |
Justice et al. | Quantitative proteomic analysis of enriched nuclear fractions from BK polyomavirus-infected primary renal proximal tubule epithelial cells | |
Marbawati et al. | Effects of curcumin and pentagamavunon-0 against dengue-2 virus Infection in vero cells; an in vitro study | |
Ivanov et al. | Screening of Russian medicinal and edible plant extracts for angiotensin I-converting enzyme (ACE I) inhibitory activity | |
Mao et al. | Herbal formula SYJN increases neurotrophin-3 and nerve growth factor expression in brain regions of rats exposed to chronic unpredictable stress | |
Odimegwu et al. | Anti-respiratory syncytial virus activities of leaf extracts of Alchornea cordifolia and Alchornea floribunda | |
Boo et al. | Anti-bacterial and anti-viral activity of extracts from Paeonia lactiflora roots | |
Saadh | Silver nanoparticles inhibit goatpox virus replication | |
Leclerc et al. | Progression of herpesvirus infection remodels mitochondrial organization and metabolism |